



ASX ANNOUNCEMENT

Control Bionics Integrates Apple's BCI Protocol to Deliver Next-Generation Accessibility Solutions

Melbourne, Australia — 11 November 2025 — Control Bionics Limited (ASX: CBL), a global leader in augmentative and alternative communication (AAC) technology, today announced its implementation of Apple's new Brain-Computer Interface (BCI) Human Interface Device (HID) protocol.

Control Bionics is **transforming** how users can interact with Apple devices through **neural and motion-based** input.

This capability will underpin a new generation of CBL's iOS-based AAC solutions, delivering faster setup, greater reliability, and more intuitive control for people living with severe speech and physical impairments.

By integrating Apple's BCI HID protocol into its NeuroNode® and NeuroNode Trilogy® product lines, Control Bionics will significantly simplify device setup and enhance real-time neural feedback for users — marking a major step forward in making AAC more seamless and accessible.

Simpler Setup, Smarter Feedback, and Automatic Activation

Apple's BCI HID protocol transforms how users can interact with Apple devices through neural and motion-based input. For Control Bionics, this means three immediate benefits:

- 1. Reduced Setup Complexity & User Error**
The BCI HID protocol streamlines iOS Switch Control setup, reducing common pain points such as configuring scanning times and modes. This advancement eliminates barriers to setup for users and caregivers, reducing the need to configure settings and enabling a genuine plug-and-play experience for NeuroNode users.
- 2. Improved Neural Signal Quality & Visual Feedback**
By allowing visual signal feedback to appear natively within the iOS interface, users can now confirm neural connection quality at a glance and recalibrate if needed. This enhancement helps users to monitor and maintain a consistent wireless connection — a frequent challenge in assistive tech — ensuring greater consistency and confidence in communication.
- 3. Automatic Switch Control Activation**
When a NeuroNode device connects or wakes, Switch Control now launches automatically, eliminating unnecessary steps and providing instant access to communication tools.

Control Bionics has released these features in beta to existing customers and in turn will provide feedback to Apple to further improve the protocol to help people with accessibility needs.

CONTROL BIONICS

A Global Platform for Funded AAC Solutions

With thousands of active users worldwide, an established **HCPCS reimbursement code in the United States**, and **NDIS funding approval in Australia**, Control Bionics is uniquely positioned to bring these enhanced BCI solutions to market immediately. The integration of Apple's BCI HID will strengthen CBL's presence across the US, Australian, and international AAC landscapes — empowering users to communicate and connect more easily than ever before.

Quotes

Jeremy Steele, CEO of Control Bionics, said:

“Integrating Apple's BCI protocol marks a defining moment for Control Bionics and for AAC innovation globally. For the first time, we can deliver a truly integrated neural-control experience within iOS — reducing setup friction, improving signal monitoring, and making communication faster and more intuitive. This new developer tool from Apple helps us to advance our mission: to give people with disabilities the fastest, simplest path to independence and expression.”

Existing Control Bionics' customer Ross Gonis (from Melbourne) with his wife Mary, said the following about their experience with Apple's BCI protocol through the NeuroNode:

“It is truly amazing Ross can see his neuro strength in real time – the Apple BCI has opened a new door for Ross in accessing technology. It helps Ross engage more independently”.

They also added “It is empowering and its life changing – thanks to Apple and Control Bionics”.

This announcement is authorised by Control Bionics CEO, Jeremy Steele.

Investors and Media

Jeremy Steele – CEO and Managing Director

jsteele@controlbionics.com

Brett Crowley - Company Secretary

brettcrowley@controlbionics.com

Investor Relations:

Joe Durak

Executive Director & Founder

Lynx Advisors

joe@lynxadvisors.com.au

+61 414 465 582

For further information visit the website: <https://www.controlbionics.com/>

Control Bionics Limited

Registered Office: Level 4, 11-13 Pearson Street, Cremorne, Vic., 3121

T: +61 3 9897 3576 W: www.controlbionics.com

ABN: 45 115 465 462

CONTROL BIONICS

About Control Bionics:

Control Bionics is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses such as Motor Neurone Disease (MND) and Amyotrophic Lateral Sclerosis (ALS).

About NeuroNode

Our core patented NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as EMG (Electromyography) output. This output is then sent wirelessly via the NeuroNode to a personal computer, enabling speech and other computer controlled functions like email and texting. Our technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse, and the NeuroNode acts as like the mouse button. Control Bionics is the only such product to harness three modalities – touch, eye and NeuroNode control – which combined yield unique benefits in terms of the ability of patients to express themselves with significantly faster speed and less fatigue.

About NeuroStrip

Control Bionics is currently commercialising its most recent advancement in its technology, the NeuroStrip. This wearable, miniaturised EMG device provides the business with the opportunity to enter new markets such as health diagnostics, sports performance and rehabilitation to name only a few potential markets.

Control Bionics has a 22% investment in Neuro Elite Athletics to drive rapid growth of their NeuroBounce program in the US and Australia

Control Bionics operates in North America, Australia, Singapore and Japan.